BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+11.22%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$10.3B
AUM Growth
+$10.3B
(+14%)
Cap. Flow
+$826M
Cap. Flow
% of AUM
8.01%
Top 10 Holdings %
Top 10 Hldgs %
81.62%
Holding
101
New
12
Increased
23
Reduced
8
Closed
11
Top Buys
| 1 |
Insmed
INSM
|
$235M |
| 2 |
Summit Therapeutics
SMMT
|
$198M |
| 3 |
Alkermes
ALKS
|
$55.1M |
| 4 |
Revolution Medicines
RVMD
|
$52.5M |
| 5 |
Structure Therapeutics
GPCR
|
$44.5M |
Top Sells
| 1 |
CRISPR Therapeutics
CRSP
|
$22.3M |
| 2 |
argenx
ARGX
|
$22M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$17.6M |
| 4 |
TSVT
2seventy bio
TSVT
|
$12.3M |
| 5 |
Akero Therapeutics
AKRO
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cidara Therapeutics
CDTX
$1.62B
| $11.1M | 0.11% |
+227,272
| New | +$11.1M |
|
52
Arcellx
ACLX
$3.92B
| $11M | 0.11% |
+166,825
| New | +$11M |
|
53
Nuvalent
NUVL
$5.71B
| $11M | 0.11% |
+143,937
| New | +$11M |
|
54
Spyre Therapeutics
SYRE
$1.02B
| $9.38M | 0.09% |
+626,703
| New | +$9.38M |
|
55
Taysha Gene Therapies
TSHA
$797M
| $9.25M | 0.09% |
4,004,756
| – | – |
|
56
Prelude Therapeutics
PRLD
$64M
| $8.19M | 0.08% |
10,123,824
| – | – |
|
57
Crinetics Pharmaceuticals
CRNX
$3.28B
| $8.05M | 0.08% |
+280,000
| New | +$8.05M |
|
58
CytomX Therapeutics
CTMX
$351M
| $7.91M | 0.08% |
+3,484,226
| New | +$7.91M |
|
59
Sagimet Biosciences
SGMT
$245M
| $7.26M | 0.07% |
952,996
| – | – |
|
|
SION
60
Sionna Therapeutics, Inc. Common Stock
SION
$1.15B
| $6.94M | 0.07% |
400,000
| – | – |
|
61
Agios Pharmaceuticals
AGIO
$2.34B
| $6.31M | 0.06% |
+189,866
| New | +$6.31M |
|
|
RAPP
62
Rapport Therapeutics
RAPP
$589M
| $6.25M | 0.06% |
+550,090
| New | +$6.25M |
|
63
Skye Bioscience
SKYE
$106M
| $6.06M | 0.06% |
1,450,638
| – | – |
|
64
Design Therapeutics
DSGN
$328M
| $5.77M | 0.06% |
1,712,882
-30,843
| -2% | -$104K |
|
65
KALA BIO
KALA
$85.2M
| $5.72M | 0.06% |
1,201,894
| – | – |
|
66
Sana Biotechnology
SANA
$752M
| $5.54M | 0.05% |
2,030,949
| – | – |
|
67
Xencor
XNCR
$592M
| $5.27M | 0.05% |
670,431
| – | – |
|
|
ALMS
68
Alumis Inc. Common Stock
ALMS
$494M
| $4.69M | 0.05% |
1,562,500
| – | – |
|
|
IGMS
69
DELISTED
IGM Biosciences
IGMS
| $4.59M | 0.04% |
4,096,210
+953
| +0% | +$1.07K |
|
70
TScan Therapeutics
TCRX
$102M
| $4.04M | 0.04% |
2,784,792
| – | – |
|
71
Relay Therapeutics
RLAY
$669M
| $4.01M | 0.04% |
1,160,117
| – | – |
|
72
Fate Therapeutics
FATE
$123M
| $2.78M | 0.03% |
2,485,018
-773,384
| -24% | -$866K |
|
73
Vir Biotechnology
VIR
$750M
| $2.73M | 0.03% |
542,539
| – | – |
|
74
Enliven Therapeutics
ELVN
$1.24B
| $2.3M | 0.02% |
114,833
| – | – |
|
75
Wave Life Sciences
WVE
$1.17B
| $2.24M | 0.02% |
344,063
| – | – |
|